Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Equity offering: 11,538,462 shares at $13.00 per share, creating substantial shareholder dilution.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Equity offering: 11,538,462 shares at $13.00 per share, creating substantial shareholder dilution
- Underwriter 30-day option for 1,730,769 additional shares, potentially increasing dilution
- Expected net proceeds approximately $161.8 million, assuming full option exercise
- Capital raise supports liquidity and financing flexibility, with closing expected November 20, 2026
- J.P. Morgan and TD Securities serving as underwriter representatives, signaling institutional distribution of the offering
Item 8.01 · Other Events
- Underwritten public offering priced November 18, 2026, creating potential equity financing and shareholder dilution
- Exhibit 99.1 contains the offering price, size, and use of proceeds relevant to valuation and liquidity
- Transaction execution indicates access to public capital markets for ongoing corporate needs
Item EX-99.1 · Exhibit EX-99.1
- $150.0 million gross equity financing through 11,538,462 shares priced at $13.00
- Potential additional dilution from underwriters’ 30-day option for 1,730,769 shares
- Proceeds strengthen funding for late-stage oncology programs, including GPS and SLS009
- Expected closing November 20, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.